FoRx Therapeutics develops FORX-428, an oral PARG enzyme inhibitor for advanced solid tumours, now in Phase 1 trials. The USD 50 million Series A, including the first close from June 2024, will fund the trial through to first results.
- Announced on
- Round
- Series A
- Amount
- USD 50 M
- Location
- Basel, canton of Basel-Stadt
- Sector
- Biotech & life sciences
Investors
- EQT Life Sciences
- Pfizer Ventures
- Novartis Venture Fund
- M Ventures
Preparing a similar round?
The diagnostic shows you the instruments and investors that fit your stage.
Start the diagnostic